Format

Send to

Choose Destination
Alzheimers Dement. 2015 Jul;11(7):865-84. doi: 10.1016/j.jalz.2015.04.005.

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.

Author information

1
Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA; Department of Radiology, University of California, San Francisco, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. Electronic address: michael.weiner@ucsf.edu.
2
Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA.
3
Department of Neurosciences, University of California- San Diego, La Jolla, CA, USA.
4
Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, Davis, CA, USA.
5
Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, MO, USA; Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
6
Neurology Early Clinical Development, Biogen Idec, Cambridge, MA, USA.
7
Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, San Diego, CA, USA.
8
Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
9
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
10
Helen Wills Neuroscience Institute and the School of Public Health, University of California Berkeley, Berkeley, CA, USA.
11
Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
12
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
13
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
14
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
15
Imaging Genetics Center, Institute for Neuroimaging and Informatics, University of Southern California, Marina Del Rey, CA, USA.
16
Laboratory of Neuroimaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of University of Southern California Los Angeles, CA, USA.
17
Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Alzheimer's Disease Core Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Udall Parkinson's Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Abstract

INTRODUCTION:

The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials.

METHODS:

We searched for ADNI publications using established methods.

RESULTS:

ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis.

DISCUSSION:

ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.

KEYWORDS:

AD biomarker signature; Alzheimer's disease; Amyloid phenotyping; Clinical trial biomarkers; Data-sharing; Tau imaging; Worldwide ADNI

PMID:
26194320
PMCID:
PMC4659407
DOI:
10.1016/j.jalz.2015.04.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center